Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Experimental | 6 | 2021 | 87 | 2.740 |
Why?
|
| Nimodipine | 3 | 2023 | 3 | 2.470 |
Why?
|
| Dantrolene | 3 | 2023 | 3 | 1.790 |
Why?
|
| Vasospasm, Intracranial | 2 | 2021 | 16 | 1.540 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2012 | 26 | 1.460 |
Why?
|
| Cardiomyopathies | 4 | 2009 | 55 | 1.210 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2023 | 83 | 0.990 |
Why?
|
| Oxidative Stress | 3 | 2018 | 874 | 0.900 |
Why?
|
| Hemodynamics | 3 | 2011 | 86 | 0.820 |
Why?
|
| Angiotensin II | 4 | 2015 | 92 | 0.800 |
Why?
|
| Rats | 12 | 2023 | 3261 | 0.790 |
Why?
|
| Caffeine | 2 | 2018 | 26 | 0.770 |
Why?
|
| Serotonin | 3 | 2021 | 114 | 0.730 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 77 | 0.720 |
Why?
|
| Animals | 23 | 2023 | 14307 | 0.690 |
Why?
|
| Blood Glucose | 3 | 2015 | 333 | 0.660 |
Why?
|
| Heart | 2 | 2014 | 178 | 0.660 |
Why?
|
| Propanolamines | 2 | 2008 | 12 | 0.650 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2023 | 1534 | 0.640 |
Why?
|
| Lactation | 1 | 2018 | 38 | 0.640 |
Why?
|
| Cricetinae | 9 | 2012 | 217 | 0.640 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 50 | 0.630 |
Why?
|
| Cerebellum | 1 | 2018 | 69 | 0.630 |
Why?
|
| Vasoconstriction | 3 | 2006 | 40 | 0.630 |
Why?
|
| Cardiac Output | 7 | 2014 | 19 | 0.630 |
Why?
|
| Seizures | 1 | 2018 | 67 | 0.630 |
Why?
|
| Carbazoles | 2 | 2008 | 43 | 0.620 |
Why?
|
| Vasodilator Agents | 4 | 2019 | 54 | 0.600 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 12 | 0.560 |
Why?
|
| Coronary Vessels | 3 | 2006 | 93 | 0.560 |
Why?
|
| Simvastatin | 2 | 2014 | 28 | 0.560 |
Why?
|
| Mothers | 1 | 2018 | 164 | 0.550 |
Why?
|
| Pyrroles | 2 | 2014 | 54 | 0.550 |
Why?
|
| Gastric Bypass | 1 | 2015 | 14 | 0.540 |
Why?
|
| Renin-Angiotensin System | 4 | 2013 | 33 | 0.530 |
Why?
|
| Lipids | 2 | 2015 | 222 | 0.530 |
Why?
|
| Celiac Artery | 1 | 2015 | 1 | 0.530 |
Why?
|
| Motor Activity | 1 | 2018 | 393 | 0.520 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2021 | 127 | 0.520 |
Why?
|
| Resistance Training | 1 | 2015 | 17 | 0.520 |
Why?
|
| Male | 24 | 2021 | 18870 | 0.510 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2012 | 37 | 0.510 |
Why?
|
| Endothelium, Vascular | 4 | 2019 | 229 | 0.500 |
Why?
|
| Toremifene | 2 | 2003 | 4 | 0.490 |
Why?
|
| Estrogen Antagonists | 2 | 2003 | 26 | 0.480 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 105 | 0.480 |
Why?
|
| Ovariectomy | 2 | 2003 | 104 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 58 | 0.470 |
Why?
|
| Blood Pressure | 7 | 2015 | 613 | 0.460 |
Why?
|
| Hypertension | 3 | 2013 | 770 | 0.450 |
Why?
|
| Fumarates | 1 | 2012 | 11 | 0.440 |
Why?
|
| Renin | 1 | 2012 | 29 | 0.430 |
Why?
|
| Etomidate | 1 | 2011 | 1 | 0.420 |
Why?
|
| Mesocricetus | 5 | 2010 | 53 | 0.420 |
Why?
|
| Diabetes Complications | 2 | 2013 | 91 | 0.420 |
Why?
|
| Ketamine | 1 | 2011 | 11 | 0.420 |
Why?
|
| Propofol | 1 | 2011 | 8 | 0.420 |
Why?
|
| Amides | 1 | 2012 | 66 | 0.410 |
Why?
|
| Anesthetics | 1 | 2011 | 10 | 0.410 |
Why?
|
| Puerto Rico | 7 | 2015 | 1352 | 0.410 |
Why?
|
| Disease Models, Animal | 7 | 2012 | 1300 | 0.410 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 88 | 0.400 |
Why?
|
| Losartan | 2 | 2008 | 31 | 0.400 |
Why?
|
| Acetylcholine | 4 | 2019 | 68 | 0.390 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 64 | 0.390 |
Why?
|
| Time Factors | 5 | 2018 | 1681 | 0.390 |
Why?
|
| Aorta, Thoracic | 2 | 2010 | 24 | 0.380 |
Why?
|
| Acetylcysteine | 1 | 2010 | 58 | 0.380 |
Why?
|
| Exercise | 1 | 2015 | 524 | 0.360 |
Why?
|
| Coronary Circulation | 1 | 2009 | 27 | 0.360 |
Why?
|
| Antioxidants | 2 | 2010 | 386 | 0.360 |
Why?
|
| Heart Rate | 4 | 2014 | 248 | 0.350 |
Why?
|
| Potassium Chloride | 2 | 2006 | 25 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 592 | 0.350 |
Why?
|
| Enalapril | 1 | 2008 | 6 | 0.340 |
Why?
|
| Disease Progression | 5 | 2015 | 580 | 0.330 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2008 | 91 | 0.320 |
Why?
|
| Muscle Contraction | 3 | 2021 | 63 | 0.310 |
Why?
|
| Syncope | 1 | 2007 | 3 | 0.310 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 217 | 0.300 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 628 | 0.290 |
Why?
|
| Streptozocin | 2 | 2021 | 21 | 0.280 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 38 | 0.280 |
Why?
|
| Caregivers | 1 | 2008 | 167 | 0.280 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 104 | 0.270 |
Why?
|
| Nitric Oxide | 2 | 2005 | 287 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 984 | 0.260 |
Why?
|
| Aging | 1 | 2009 | 639 | 0.250 |
Why?
|
| Stroke Volume | 3 | 2011 | 97 | 0.250 |
Why?
|
| Doxorubicin | 1 | 2005 | 80 | 0.250 |
Why?
|
| Humans | 17 | 2021 | 34853 | 0.250 |
Why?
|
| Blood Vessels | 1 | 2003 | 32 | 0.240 |
Why?
|
| Cardiovascular System | 1 | 2003 | 30 | 0.230 |
Why?
|
| Reactive Oxygen Species | 1 | 2005 | 416 | 0.230 |
Why?
|
| Cerebrovascular Circulation | 1 | 2023 | 71 | 0.220 |
Why?
|
| Stress, Psychological | 1 | 2008 | 541 | 0.220 |
Why?
|
| Insulin Resistance | 2 | 2015 | 177 | 0.210 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 5 | 0.210 |
Why?
|
| Calcium Channel Blockers | 1 | 2021 | 56 | 0.200 |
Why?
|
| Endothelin-1 | 2 | 2015 | 54 | 0.200 |
Why?
|
| Pravastatin | 2 | 2014 | 6 | 0.200 |
Why?
|
| Gambling | 1 | 2020 | 15 | 0.190 |
Why?
|
| Phenylephrine | 1 | 2019 | 34 | 0.180 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2018 | 4 | 0.180 |
Why?
|
| Behavior, Addictive | 1 | 2020 | 33 | 0.180 |
Why?
|
| Self Efficacy | 1 | 2020 | 173 | 0.170 |
Why?
|
| Female | 9 | 2020 | 19873 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 7 | 0.160 |
Why?
|
| Gait | 1 | 2018 | 21 | 0.160 |
Why?
|
| Cognition Disorders | 1 | 2020 | 233 | 0.160 |
Why?
|
| Adenosine | 1 | 2018 | 54 | 0.160 |
Why?
|
| Fever | 1 | 2018 | 57 | 0.160 |
Why?
|
| Middle Aged | 7 | 2020 | 9642 | 0.160 |
Why?
|
| Echocardiography | 2 | 2010 | 144 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2015 | 1961 | 0.150 |
Why?
|
| Adult | 6 | 2020 | 11034 | 0.150 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 2008 | 24 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2008 | 63 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2015 | 26 | 0.140 |
Why?
|
| Swine | 2 | 2006 | 182 | 0.130 |
Why?
|
| Taurine | 1 | 2015 | 3 | 0.130 |
Why?
|
| Paullinia | 1 | 2015 | 3 | 0.130 |
Why?
|
| Spain | 2 | 2020 | 33 | 0.130 |
Why?
|
| Weight Loss | 1 | 2015 | 124 | 0.130 |
Why?
|
| United States | 2 | 2015 | 3894 | 0.120 |
Why?
|
| Nitroprusside | 2 | 2003 | 13 | 0.120 |
Why?
|
| Isometric Contraction | 2 | 2003 | 21 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 145 | 0.120 |
Why?
|
| Norepinephrine | 2 | 2003 | 107 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 147 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2013 | 7 | 0.120 |
Why?
|
| Body Weight | 1 | 2015 | 404 | 0.120 |
Why?
|
| Acid-Base Imbalance | 1 | 2013 | 3 | 0.110 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 7 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 2333 | 0.110 |
Why?
|
| Critical Illness | 1 | 2013 | 37 | 0.110 |
Why?
|
| Pregnancy | 1 | 2018 | 1503 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 142 | 0.110 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 35 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 48 | 0.110 |
Why?
|
| Valine | 1 | 2012 | 31 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2013 | 64 | 0.110 |
Why?
|
| Magnesium | 1 | 2013 | 95 | 0.110 |
Why?
|
| Incidence | 2 | 2013 | 882 | 0.110 |
Why?
|
| Tetrazoles | 1 | 2012 | 49 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 58 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 99 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2015 | 775 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2013 | 131 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 212 | 0.090 |
Why?
|
| Quinuclidines | 1 | 2009 | 5 | 0.090 |
Why?
|
| Tropanes | 1 | 2009 | 6 | 0.090 |
Why?
|
| Muscarinic Antagonists | 1 | 2009 | 12 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 6448 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 528 | 0.090 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2009 | 31 | 0.090 |
Why?
|
| Cytokines | 1 | 2013 | 569 | 0.090 |
Why?
|
| Inflammation | 1 | 2013 | 577 | 0.080 |
Why?
|
| Acetamides | 1 | 2008 | 12 | 0.080 |
Why?
|
| Antiparkinson Agents | 1 | 2008 | 11 | 0.080 |
Why?
|
| Superoxides | 1 | 2008 | 51 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2008 | 115 | 0.080 |
Why?
|
| Heart Failure | 1 | 2010 | 230 | 0.080 |
Why?
|
| Age Factors | 1 | 2010 | 1007 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 965 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 39 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2008 | 112 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2008 | 1349 | 0.070 |
Why?
|
| Vasodilation | 1 | 2007 | 65 | 0.070 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2006 | 6 | 0.070 |
Why?
|
| Ketanserin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Receptors, Serotonin, 5-HT1 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2006 | 5 | 0.070 |
Why?
|
| Propranolol | 1 | 2006 | 17 | 0.070 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 3 | 0.070 |
Why?
|
| Serotonin Antagonists | 1 | 2006 | 22 | 0.070 |
Why?
|
| Lovastatin | 1 | 2006 | 10 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2006 | 23 | 0.070 |
Why?
|
| Binding, Competitive | 1 | 2006 | 103 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 30 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 358 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2005 | 72 | 0.070 |
Why?
|
| Rats, Inbred SHR | 1 | 2005 | 31 | 0.070 |
Why?
|
| Systole | 1 | 2005 | 65 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 88 | 0.060 |
Why?
|
| Risk Factors | 1 | 2013 | 3414 | 0.060 |
Why?
|
| Models, Animal | 1 | 2005 | 131 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 165 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2005 | 154 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 195 | 0.060 |
Why?
|
| Muscle Relaxation | 1 | 2003 | 17 | 0.060 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 34 | 0.060 |
Why?
|
| Hormones | 1 | 2003 | 51 | 0.060 |
Why?
|
| Aorta, Abdominal | 1 | 2003 | 10 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 103 | 0.060 |
Why?
|
| Protein Binding | 1 | 2006 | 913 | 0.060 |
Why?
|
| Aorta | 1 | 2003 | 161 | 0.060 |
Why?
|
| Myocardium | 1 | 2005 | 224 | 0.060 |
Why?
|
| Depression | 1 | 2008 | 664 | 0.050 |
Why?
|
| Estradiol | 1 | 2003 | 244 | 0.050 |
Why?
|
| Anxiety | 1 | 2008 | 705 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 284 | 0.050 |
Why?
|
| Reward | 1 | 2020 | 73 | 0.040 |
Why?
|
| Radioligand Assay | 2 | 2009 | 61 | 0.040 |
Why?
|
| Cricetulus | 2 | 2009 | 74 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2009 | 376 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4012 | 0.040 |
Why?
|
| Infant | 2 | 2013 | 1014 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2005 | 1802 | 0.040 |
Why?
|
| Cognition | 1 | 2020 | 373 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 5035 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 1318 | 0.030 |
Why?
|
| Hypokalemia | 1 | 2013 | 11 | 0.030 |
Why?
|
| Critical Care | 1 | 2013 | 37 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 47 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2013 | 57 | 0.030 |
Why?
|
| Child | 2 | 2013 | 2875 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2013 | 154 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 160 | 0.020 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 2009 | 3 | 0.020 |
Why?
|
| Esters | 1 | 2009 | 28 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2009 | 75 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 107 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2009 | 141 | 0.020 |
Why?
|
| Drug Stability | 1 | 2009 | 110 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 162 | 0.020 |
Why?
|
| Catalepsy | 1 | 2008 | 8 | 0.020 |
Why?
|
| Haloperidol | 1 | 2008 | 27 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 115 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2008 | 69 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 130 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2008 | 202 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 310 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 143 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2006 | 5 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2006 | 92 | 0.020 |
Why?
|
| Water | 1 | 2008 | 283 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 1289 | 0.020 |
Why?
|
| Mice | 1 | 2009 | 5668 | 0.010 |
Why?
|